SCHEMBL320481

SCHEMBL320481

CC(=O)c1cc(C(F)(F)F)ccc1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
P2RX1 P51575 9/20 0.49
TMPRSS4 Q9NRS4 9/20 0.49
P2RX4 Q99571 4/20 0.49
P2RX7 Q99572 4/20 0.49
MAPT P10636 1/20 0.47
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
HSD17B10 Q99714 2/20 0.46
USP2 O75604 1/20 0.46
CYP2C19 P33261 1/20 0.46
SLC2A1 P11166 1/20 0.46
IKBKB O14920 1/20 0.45
CHUK O15111 1/20 0.45
KDR P35968 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30062195 1.00 CES2 (0.52) CES2MEN1KMT2AP2RX1TMPRSS4
SCHEMBL323648 0.86 KIF11 (0.48) MEN1KMT2AP2RX1TMPRSS4P2RX4
SCHEMBL29540816 0.85 MAPT (0.57) CES2MEN1KMT2AP2RX1TMPRSS4
SCHEMBL1451777 0.85 MAPT (0.57) CES2MEN1KMT2AP2RX1TMPRSS4
SCHEMBL3925394 0.85 CES2 (0.52) CES2P2RX1MAPTKDM4EALDH1A1
SCHEMBL21852902 0.84 CES2 (0.55) CES2MEN1KMT2AMAPTHTT
SCHEMBL130628 0.82 ALDH1A1 (0.59) CES2MEN1KMT2ATMPRSS4HTT
SCHEMBL6581882 0.82 HSP90AA1 (0.60) MEN1KMT2AP2RX1MAPTHTT
SCHEMBL10455841 0.81 CES2 (0.52) CES2MEN1KMT2AP2RX1TMPRSS4
SCHEMBL13609958 0.81 ESR1 (0.53) MAPTHTTL3MBTL1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024097721-A1 TARGETING ALLOSTERIC AND ORTHOSTERIC POCKETS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PETRA PHARMA CORPORATION (US) 2024-05-10 WO disclosed
EP-4347040-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF CANCER Petra Pharma Corporation (US) 2024-04-10 EP disclosed
CN-117769546-A Allosteric ketene inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease 佩特拉制药公司 2024-03-26 CN disclosed
EP-4333984-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE Petra Pharma Corporation (US) 2024-03-13 EP disclosed
CN-117693506-A Allosteric ketone inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease 佩特拉制药公司 2024-03-12 CN disclosed
US-20240051948-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PETRA PHARMA CORP (US) 2024-02-15 US disclosed
US-11878970-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PETRA PHARMA CORPORATION (US) 2024-01-23 US disclosed
US-11873295-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PETRA PHARMA CORPORATION (US) 2024-01-16 US disclosed
CN-116829563-A Cerium-ethylenediamine ketone and cerium-salen complexes and their use in organic electronics 克雷多西斯有限公司 2023-09-29 CN disclosed
EP-4244910-A1 CERIUM-ETHYLENEDIAMINE KETONE-TYPE AND CERIUM-SALEN-TYPE COMPLEXES AND USE THEREOF IN ORGANIC ELECTRONICS Credoxys GmbH c/o Institut for Applied Physics (DE) 2023-09-20 EP disclosed
US-20030109574-A1 Process for producing 4-substituted benzopyran derivatives CENTRAL GLASS COMPANY, LIMITED (JP) 2003-06-12 US disclosed
EP-1309531-A1 DERIVATIVES OF 4-(TRIFLUOROMETHYL)-PHENOL AND 4-(TRIFLUOROMETHYLPHENYL)-2-(TETRAHYDROPYRANYL) ETHER AND METHOD FOR PRODUCING THE SAME BASF AKTIENGESELLSCHAFT (DE) 2003-05-14 EP disclosed
EP-1298129-A2 Process for producing 4-sustituted benzopyran derivatives Central Glass Company, Limited (JP) 2003-04-02 EP disclosed
WO-2002014250-A1 DERIVATIVES OF 4-(TRIFLUOROMETHYL)-PHENOL AND 4-(TRIFLUOROMETHYLPHENYL)-2-(TETRAHYDROPYRANYL) ETHER AND METHOD FOR PRODUCING THE SAME BASF AKTIENGESELLSCHAFT (DE) 2002-02-21 WO disclosed
US-4479007-A Chroman-4-ones and process for preparing same BAYER AKTIENGESELLSCHAFT (DE) 1984-10-23 US disclosed
US-4415741-A REACTING O-HYDROXYACETOPHENONE AND CYCLOPENTANONE BAYER AKTIENGESELLSCHAFT (DE) 1983-11-15 US disclosed
US-4307020-A REACTING AN 0-HYDROXYACETOPHENONE WITH A GLYOXYLIC ACID BAYER AKTIENGESELLSCHAFT (DE) 1981-12-22 US disclosed
US-4285965-A FUNGICIDES AND INSECTICIDES FOR PLANTS BAYER AKTIENGESELLSCHAFT (DE) 1981-08-25 US disclosed
EP-0000377-B1 PROCESS FOR THE PREPARATION OF CHROMONE DERIVATIVES, NEW CHROMONE DERIVATIVES AND THEIR USE AS PLANT-PROTECTING AGENTS BAYER AG (DE) 1981-01-21 EP disclosed
US-4189498-A FUNGICIDES, ARTHROPODICIDES BAYER AKTIENGESELLSCHAFT (DE) 1980-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11878970-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PIK3CA, PIK3R4, PIK3R5 CES2 2922/4885MEN1 1313/4885KMT2A 4426/4885
US-11873295-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PIK3CA, PIK3R4, PIK3R5 CES2 2922/4885MEN1 1313/4885KMT2A 4426/4885
US-20030109574-A1 Process for producing 4-substituted benzopyran derivatives ACSL4, HAO2, ACSL6 CES2 2045/4885MEN1 4756/4885KMT2A 922/4885
US-20240051948-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 CES2 2922/4885MEN1 1313/4885KMT2A 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.